Head-to-head · verified 2026-08-05
Amble Health vs. Mochi Health: prices, fine print, and the honest verdict
Mochi Health is the cheaper tirzepatide program here — $278 vs $300 all-in at 10 mg, a $22/mo gap — but price is only the first of five things this page normalizes.
- Amble Health
- Tirzepatide, all-in at 10 mg
- $300/mo
- Semaglutide, all-in
- Not offered
- Membership fee
- None
- Commitment
- unknown
- Cancellation
- not published
- Pharmacy
- not named
- First-year total (standing rate)
- $3,600
- Price evidence
- Third-party-reported
- Last verified
- 2026-08-05
- Mochi Health
- Official site
- joinmochi.com ↗
- Tirzepatide, all-in at 10 mg
- $278/mo
- Semaglutide, all-in
- $178/mo
- Membership fee
- $79/mo, mandatory
- Commitment
- membership recurs monthly
- Cancellation
- cancel membership any time; recurs until cancelled
- Pharmacy
- company-owned compounding facility
- First-year total (standing rate)
- $3,336
- Price evidence
- Source-verified
- Last verified
- 2026-08-05
Tirzepatide pricing
On tirzepatide, Mochi Health is the cheaper program at $278 a month all-in versus Amble Health's $300 — a gap of $22 a month, $264 a year, at the 10 mg maintenance basis. Amble Health: $300 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Mochi Health: $278 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, including the mandatory $79/mo membership.
Semaglutide pricing
Only Mochi Health publishes a semaglutide price here: Semaglutide runs $178 a month all-in. Amble Health doesn't sell compounded semaglutide.
Transparency
Amble Health: Third-party-reported (verified 2026-08-05); dispensing pharmacy not publicly named. Mochi Health: Source-verified (verified 2026-08-05); names its pharmacy — company-owned compounding facility. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.
Commitment & cancellation
Amble Health: unknown; not published. Mochi Health: membership recurs monthly; cancel membership any time; recurs until cancelled; $79/mo membership recurs until cancelled.
Amble Health $300/mo vs Mochi Health $278/mo all-in at 10 mg — Mochi Health cheaper by $22/mo ($264/yr); twelve months: $3,600 vs $3,336; semaglutide: Mochi Health $178; verified floor $215 (NexLife); brand rails $349–$449. Basis: all-in monthly, 10 mg maintenance, capture-dated in the dataset.
The gap, compounded over time
Here is what the $22 monthly spread between these two actually buys back over a treatment course — one month, $22; six months, $132; a year, $264; two years of maintenance, $528. Every figure is the all-in maintenance basis; the arithmetic reruns from the dataset.
The 24-month ledger
Maintenance therapies deserve maintenance math: over two years at standing rates, Amble Health bills $7,200 and Mochi Health $6,672, a spread of $528 for the same molecule at the same 10 mg basis. Reference rails for the same 24 months: $5,160 at the verified floor, $10,776 on brand Zepbound at maintenance, $8,376 on Wegovy flat.
Two ladders, side by side
Put both dose ladders on the same axis and the structures argue for themselves: Amble Health holds $300 on every rung (four-month titration: exactly $1,200); Mochi Health holds $278 on every rung (four-month titration: exactly $1,112). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.
Three buyers, two invoices
The month-one starter pays $300 at Amble Health versus $278 at Mochi Health for the 2.5 mg rung — an early edge that holds once the ladder climbs. The settled 10 mg maintainer — the buyer our basis is built for — pays $3,336/year at Mochi Health against $3,600 at the other: $264 of annual daylight for the same molecule and dose.
The semaglutide board
Only Mochi Health fields a verified semaglutide price here — $178/month all-in (#6 of 19) — while Amble Health focuses its published pricing on tirzepatide. For a buyer starting on the cheaper molecule with a likely upgrade later, single-molecule programs mean a future re-shop; dual-molecule ones price the whole arc.
The five normalizations, applied to this pair
1 · All-in, not advertised. Amble Health's ranked figure is $300, with no membership to add; Mochi Health's ranked figure is $278 ($199 medication + $79 mandatory membership). 2 · Maintenance basis. Amble Health is dose-flat, so its entry and 10 mg figures coincide; Mochi Health is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. Amble Health: standing $300, no prepaid tier; Mochi Health: standing $278, no prepaid tier — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Amble Health: third-party-reported, read 2026-08-05; Mochi Health: source-verified, read 2026-08-05. 5 · Pharmacy weighed. Amble Health names no pharmacy; Mochi Health names company-owned compounding facility — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.
Fine print, itemized
Amble Health: no membership — the medication figure is the billed figure; not published; commitment: unknown. Mochi Health: a mandatory $79/mo membership folded into our all-in figure; cancel membership any time; recurs until cancelled; commitment: membership recurs monthly. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.
Transparency, audited
Amble Health carries third-party-reported pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Mochi Health carries source-verified pricing (last read 2026-08-05); pharmacy disclosure is its strong suit — company-owned compounding facility, owned facility. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.
Switching between them
Moving from Amble Health to Mochi Health (or back) is administratively unglamorous: complete the new program's intake, let its prescriber issue a fresh prescription to its pharmacy, and cancel the old subscription in writing — prescriptions don't transfer between telehealth programs, and neither do prepaid balances, which is the quiet reason month-to-month terms are worth their premium.
Refills, shipping, and the week-to-week reality
The unglamorous layer — how the medication actually reaches you and stays on schedule — splits like this: Amble Health: shipping unknown; consultation unknown. Mochi Health: shipping included; consultation video visits included in membership; video visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.
Who should pick which
Pick Amble Health if you refuse membership fees on principle. Pick Mochi Health if the $22/month tirzepatide saving is the point; a named pharmacy is non-negotiable for you; unlimited included clinician and dietitian visits matter more than the last $60. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.
If neither one fits
The dataset's bench is deep; the closest verified third options to this matchup's price band are Found at $289 (flat, no membership); ShedRx at $289 (dose-scaled, no membership); OrderlyMeds at $299 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.
The brand benchmark both must beat
Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $2,052/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.
The verdict
On the numbers alone, Mochi Health is the cheaper tirzepatide program by $22/mo and it doesn't trade that price for opacity. Both records, with dates and sources, live in the pricing database.
Quick answers
Which is cheaper for tirzepatide, Amble Health or Mochi Health?
Mochi Health: $278/mo all-in at 10 mg versus $300 — a $22/mo difference ($264/yr).
Can I switch between them?
Yes — patients move between telehealth programs routinely; you'll complete the new program's intake and prescriptions restart there. If you're also switching molecule or from compounded to brand, loop in the prescriber; our switching guide covers the clinical side.
What do Amble Health and Mochi Health cost over 12 months?
At standing all-in rates: Amble Health $3,600, Mochi Health $3,336 — a $264 gap before any prepaid terms.
Do either charge membership fees?
Amble Health: none. Mochi Health: $79/mo, mandatory (included in our all-in figure).
Which is easier to cancel, Amble Health or Mochi Health?
Amble Health: not published Mochi Health: cancel membership any time; recurs until cancelled Cancel in writing either way; memberships cancel separately.
Is there a brand alternative to both?
Yes — Zepbound at $299–$449 via LillyDirect/retail (about $350 on TrumpRx; ~$50 for newly eligible Medicare patients) and Wegovy at a flat $349: FDA-approved products whose prices now sit close enough to make the comparison real.